Ad5-nCoV

Summary

Ad5-nCoV is a vaccine^[1]. Ad5-nCoV draws 37 Wikipedia views per month (vaccine category, ranking #2 of 7).^[2]

Key Facts

• Ad5-nCoV's image is recorded as CanSino Convidecia.jpg^[3].
• Ad5-nCoV's instance of is recorded as vaccine^[4].
• Ad5-nCoV's manufacturer is recorded as Petrovax^[5].
• Ad5-nCoV's developer is recorded as CanSino Biologics^[6].
• Ad5-nCoV's developer is recorded as PLA Academy of Military Medical Sciences^[7].
• Ad5-nCoV's ATC code is recorded as J07BX03^[8].
• Ad5-nCoV's subclass of is recorded as COVID-19 vaccine^[9].
• Ad5-nCoV's subclass of is recorded as adenovirus-based vaccine^[10].
• Ad5-nCoV's subclass of is recorded as vaccine candidate^[11].
• Ad5-nCoV's Commons category is recorded as Convidecia^[12].
• Ad5-nCoV's route of administration is recorded as intramuscular injection^[13].
• Ad5-nCoV's UNII is recorded as 5AHC3V2UQS^[14].
• Ad5-nCoV's DrugBank ID is recorded as DB15655^[15].
• Ad5-nCoV's described by source is recorded as Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial^[16].
• Ad5-nCoV's described by source is recorded as A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)^[17].
• Ad5-nCoV's described by source is recorded as Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada^[18].
• Ad5-nCoV's described by source is recorded as Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial^[19].
• Ad5-nCoV's described by source is recorded as A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)^[20].
• Ad5-nCoV's described by source is recorded as A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)^[21].
• Ad5-nCoV's described by source is recorded as A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)^[22].
• Ad5-nCoV's described by source is recorded as Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19^[23].
• Ad5-nCoV's described by source is recorded as Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above^[24].
• Ad5-nCoV's official name is recorded as {'lang': 'en', 'text': 'Convidecia'}^[25].
• Ad5-nCoV's official name is recorded as {'lang': 'en', 'text': 'PakVak'}^[26].
• Ad5-nCoV's side effect is recorded as fever^[27].

Why It Matters

Ad5-nCoV draws 37 Wikipedia views per month (vaccine category, ranking #2 of 7).^[2] Ad5-nCoV has Wikipedia articles in 18 language editions, a strong signal of global cultural recognition.^[28] Ad5-nCoV is known by 14 alternative names across languages and contexts.^[29]